688520 神州细胞
已收盘 12-24 15:00:01
资讯
新帖
简况
神州细胞向控股股东不超9亿定增获通过 中信证券建功
中金财经 · 12-08
神州细胞向控股股东不超9亿定增获通过 中信证券建功
11月4日神州细胞跌5.55%，前海开源再融资股票基金重仓该股
证券之星 · 11-04
11月4日神州细胞跌5.55%，前海开源再融资股票基金重仓该股
每周股票复盘：神州细胞（688520）股东户数增40.96%
证券之星 · 11-02
每周股票复盘：神州细胞（688520）股东户数增40.96%
神州细胞（688520）2025年三季报简析：净利润同比下降267.17%，三费占比上升明显
证券之星 · 11-01
神州细胞（688520）2025年三季报简析：净利润同比下降267.17%，三费占比上升明显
图解神州细胞三季报：第三季度单季净利润同比下降994.50%
证券之星 · 10-30
图解神州细胞三季报：第三季度单季净利润同比下降994.50%
每周股票复盘：神州细胞（688520）拟募9亿补流，控股东质押融资认购
证券之星 · 10-19
每周股票复盘：神州细胞（688520）拟募9亿补流，控股东质押融资认购
神州细胞募资9亿元“回血”，通过补贴患者扩大销售，回应：行业普遍做法
红星资本局 · 10-15
神州细胞募资9亿元“回血”，通过补贴患者扩大销售，回应：行业普遍做法
股市必读：新发布《信永中和会计师事务所（特殊普通合伙）关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的审核问询函的回复》
证券之星 · 10-15
股市必读：新发布《信永中和会计师事务所（特殊普通合伙）关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的审核问询函的回复》
每周股票复盘：神州细胞（688520）将参加科创板业绩说明会
证券之星 · 09-14
每周股票复盘：神州细胞（688520）将参加科创板业绩说明会
每周股票复盘：神州细胞（688520）股东户数下降12.74%
证券之星 · 08-31
每周股票复盘：神州细胞（688520）股东户数下降12.74%
神州细胞（688520）2025年中报简析：净利润同比下降126.87%，三费占比上升明显
证券之星 · 08-30
神州细胞（688520）2025年中报简析：净利润同比下降126.87%，三费占比上升明显
神州细胞(688520.SH)发布半年度业绩，归母净亏损3377万元，同比由盈转亏
智通财经 · 08-28
神州细胞(688520.SH)发布半年度业绩，归母净亏损3377万元，同比由盈转亏
图解神州细胞中报：第二季度单季净利润同比下降289.37%
证券之星 · 08-28
图解神州细胞中报：第二季度单季净利润同比下降289.37%
神州细胞(688520)6月30日股东户数0.98万户，较上期减少12.74%
证券之星 · 08-28
神州细胞(688520)6月30日股东户数0.98万户，较上期减少12.74%
8月14日神州细胞涨5.21%，申万菱信中证500指数优选增强A基金重仓该股
证券之星 · 08-14
8月14日神州细胞涨5.21%，申万菱信中证500指数优选增强A基金重仓该股
药代和患者涉嫌骗保 神州细胞称公司未被调查
中国经营网 · 08-09
药代和患者涉嫌骗保 神州细胞称公司未被调查
生物制品公司财务总监PK：百万年薪以上占比41% 神州细胞马洁年薪143万行业第三
新浪证券 · 08-08
生物制品公司财务总监PK：百万年薪以上占比41% 神州细胞马洁年薪143万行业第三
生物制品公司财务总监PK：50岁以上CFO占比为38% 智翔金泰刘力文为业内最年轻CFO
新浪证券 · 08-08
生物制品公司财务总监PK：50岁以上CFO占比为38% 智翔金泰刘力文为业内最年轻CFO
神州细胞今日主力净流出1.2亿 短期波动后看业绩兑现
智选洞察 · 08-07
神州细胞今日主力净流出1.2亿 短期波动后看业绩兑现
生物类似药集采启动，国内企业将迎接“价格战”
健识局 · 08-04
生物类似药集采启动，国内企业将迎接“价格战”
加载更多
公司概况
公司名称：
北京神州细胞生物技术集团股份公司
所属行业：
医药制造业
上市日期：
2020-06-22
主营业务：
北京神州细胞生物技术集团股份公司的主营业务是恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。公司的主要产品是SCT800（安佳因）、SCT400（安平希）、SCT630（安佳润）、SCT510（安贝珠）、SCT-I10A（安佑平）、SCT1000SCT650C、SCTC21C、SCTB35、SCTB14、SCTB41、SCTV02、SCTV04C、SCT520FF、SCTT11、SCTB39-1、SCTB39G、SCT640C。
发行价格：
25.64
{"stockData":{"symbol":"688520","market":"SH","secType":"STK","nameCN":"神州细胞","latestPrice":43.8,"timestamp":1766559601000,"preClose":43.7,"halted":0,"volume":2041384,"delay":0,"changeRate":0.0023,"floatShares":445000000,"shares":445000000,"eps":-0.6483,"marketStatus":"已收盘","change":0.1,"latestTime":"12-24 15:00:01","open":43.69,"high":44.42,"low":43.57,"amount":89743500,"amplitude":0.0195,"askPrice":43.81,"askSize":95,"bidPrice":43.8,"bidSize":64,"shortable":0,"etf":0,"ttmEps":-0.6483,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766626200000},"marketStatusCode":5,"adr":0,"adjPreClose":43.7,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766539800000,1766547000000],[1766552400000,1766559600000]],"highLimit":48.07,"lowLimit":39.33,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":445335714,"isCdr":false,"pbRate":-26.94,"roa":"--","roe":"0.0%","epsLYR":0.24,"committee":-0.184481,"marketValue":19506000000,"turnoverRate":0.0046,"status":0,"afterMarket":{"amount":0,"volume":0,"close":43.8,"buyVolume":0,"sellVolume":0,"time":1766561637768,"indexStatus":"已收盘 12-24 15:30:00","preClose":43.7},"floatMarketCap":19506000000},"requestUrl":"/m/hq/s/688520","defaultTab":"news","newsList":[{"id":"2589828643","title":"神州细胞向控股股东不超9亿定增获通过 中信证券建功","url":"https://stock-news.laohu8.com/highlight/detail?id=2589828643","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589828643?lang=zh_cn&edition=full","pubTime":"2025-12-08 14:53","pubTimestamp":1765176795,"startTime":"0","endTime":"0","summary":"神州细胞日前发布《关于2025年度向特定对象发行A股股票申请收到上海证券交易所审核意见通知的公告》。 神州细胞表示，公司本次向特定对象发行A股股票事项尚需获得中国证监会作出同意注册的决定后方可实施，最终能否获得中国证监会同意注册的决定及其时间尚存在不确定性。 神州细胞本次发行的保荐机构为中信证券股份有限公司，保荐代表人为丁元、黄可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251208/31850349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","LU1720050803.USD","BK1521","BK0276","LU1328615791.USD","BK1147","LU1655091616.SGD","LU0405327148.USD","LU1997244956.HKD","BK0196","BK1516","BK0012","LU1064130708.USD","LU1064131003.USD","06030","LU1255011170.USD","LU2289578879.USD","LU2148510915.USD","688520","BK0188","LU1794554557.SGD","BK1564","BK0183","LU1997245177.USD","LU1997245094.SGD","BK0028","LU2495084118.USD","LU0405327494.USD","600030"],"gpt_icon":0},{"id":"2580788522","title":"11月4日神州细胞跌5.55%，前海开源再融资股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580788522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580788522?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:29","pubTimestamp":1762244992,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日神州细胞跌5.55%，收盘报51.25元，换手率1.42%，成交量6.3万手，成交额3.26亿元。重仓神州细胞的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为前海开源基金的前海开源再融资股票。前海开源再融资股票目前规模为4.84亿元，最新净值1.428，较上一交易日下跌0.07%，近一年上涨21.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400025448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["162717","688520","BK0239"],"gpt_icon":0},{"id":"2580472831","title":"每周股票复盘：神州细胞（688520）股东户数增40.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580472831","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580472831?lang=zh_cn&edition=full","pubTime":"2025-11-02 06:21","pubTimestamp":1762035670,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，神州细胞报收于53.7元，较上周的51.99元上涨3.29%。本周，神州细胞10月31日盘中最高价报54.0元。股本股东变化股东户数变动截至2025年9月30日，神州细胞股东户数为1.37万户，较6月30日增加3995.0户，增幅40.96%。业绩披露要点财务报告神州细胞2025年三季报显示，前三季度主营收入13.12亿元，同比下降32.27%；归母净利润-2.51亿元，同比下降267.17%；扣非净利润-2.0亿元，同比下降143.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2580640417","title":"神州细胞（688520）2025年三季报简析：净利润同比下降267.17%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2580640417","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580640417?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:52","pubTimestamp":1761951130,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期神州细胞发布2025年三季报。截至本报告期末，公司营业总收入13.12亿元，同比下降32.27%，归母净利润-2.51亿元，同比下降267.17%。本报告期神州细胞三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达72.53%。去年的净利率为4.47%，算上全部成本后，公司产品或服务的附加值不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2579092144","title":"图解神州细胞三季报：第三季度单季净利润同比下降994.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579092144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579092144?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:54","pubTimestamp":1761828895,"startTime":"0","endTime":"0","summary":"证券之星消息，神州细胞2025年三季报显示，前三季度公司主营收入13.12亿元，同比下降32.27%；归母净利润-2.51亿元，同比下降267.17%；扣非净利润-2.0亿元，同比下降143.32%；其中2025年第三季度，公司单季度主营收入3.4亿元，同比下降46.25%；单季度归母净利润-2.17亿元，同比下降994.5%；单季度扣非净利润-1.64亿元，同比下降234.46%；负债率101.46%，投资收益73.43万元，财务费用6848.48万元，毛利率94.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2576041271","title":"每周股票复盘：神州细胞（688520）拟募9亿补流，控股东质押融资认购","url":"https://stock-news.laohu8.com/highlight/detail?id=2576041271","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576041271?lang=zh_cn&edition=full","pubTime":"2025-10-19 04:39","pubTimestamp":1760819948,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，神州细胞报收于52.89元，较上周的54.59元下跌3.11%。本周，神州细胞10月16日盘中最高价报56.3元。本周关注点公司公告汇总：神州细胞拟向控股股东拉萨爱力克发行不超过2500万股，募资不超9亿元用于补充流动资金，发行价36.00元/股。公司公告汇总神州细胞拟向特定对象发行A股股票，募集资金总额不超过90,000.00万元，扣除发行费用后全部用于补充流动资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2575122736","title":"神州细胞募资9亿元“回血”，通过补贴患者扩大销售，回应：行业普遍做法","url":"https://stock-news.laohu8.com/highlight/detail?id=2575122736","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575122736?lang=zh_cn&edition=full","pubTime":"2025-10-15 22:33","pubTimestamp":1760538780,"startTime":"0","endTime":"0","summary":" 红星资本局注意到，近年来神州细胞通过为患者提供补贴来扩大产品销量。10月15日，神州细胞证券部回应红星资本局称，对患者进行大额补贴是行业的普遍做法，有利于公司推广产品。红星资本局发现，销售费用和营业外支出均与公司通过给予患者补贴扩大销售有关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-15/doc-inftywai7940558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2575446342","title":"股市必读：新发布《信永中和会计师事务所（特殊普通合伙）关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的审核问询函的回复》","url":"https://stock-news.laohu8.com/highlight/detail?id=2575446342","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575446342?lang=zh_cn&edition=full","pubTime":"2025-10-15 03:47","pubTimestamp":1760471228,"startTime":"0","endTime":"0","summary":"公司公告汇总北京神州细胞生物技术集团股份公司拟向特定对象发行A股股票，募集资金总额不超过90,000.00万元，用于补充流动资金。公司已履行相关决策程序，发行定价符合规定，不存在损害中小股东利益的情形。公司于2025年9月5日收到上交所出具的审核问询函，已会同中介机构完成回复，并更新2025年半年度财务报告相关内容。本次发行尚需通过上交所审核并获中国证监会注册，最终能否获批及时间存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500003572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2567136606","title":"每周股票复盘：神州细胞（688520）将参加科创板业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2567136606","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567136606?lang=zh_cn&edition=full","pubTime":"2025-09-14 04:50","pubTimestamp":1757796620,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，神州细胞报收于60.0元，较上周的63.0元下跌4.76%。本周，神州细胞9月9日盘中最高价报64.21元。本周关注点公司公告汇总：神州细胞将参加2025年半年度科创板创新药行业集体业绩说明会。说明会后可通过上证路演中心查看召开情况及主要内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400001116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159982","688520"],"gpt_icon":0},{"id":"2563640882","title":"每周股票复盘：神州细胞（688520）股东户数下降12.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563640882","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563640882?lang=zh_cn&edition=full","pubTime":"2025-08-31 03:37","pubTimestamp":1756582631,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，神州细胞报收于63.5元，较上周的68.06元下跌6.7%。本周，神州细胞8月25日盘中最高价报70.5元。股本股东变化股东户数变动截至2025年6月30日，神州细胞股东户数为9754.0户，较3月31日减少1424.0户，减幅12.74%。神州细胞2025年半年度报告摘要神州细胞2025年半年度报告摘要显示，公司总资产3,526,218,500.07元，较上年度末增长7.38%；归属于上市公司股东的净资产110,838,929.67元，较上年度末下降21.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100000447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2563007068","title":"神州细胞（688520）2025年中报简析：净利润同比下降126.87%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2563007068","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563007068?lang=zh_cn&edition=full","pubTime":"2025-08-30 06:18","pubTimestamp":1756505902,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期神州细胞发布2025年中报。截至本报告期末，公司营业总收入9.72亿元，同比下降25.5%，归母净利润-3377.11万元，同比下降126.87%。本报告期神州细胞三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达68.51%。去年的净利率为4.47%，算上全部成本后，公司产品或服务的附加值不高。持有神州细胞最多的基金为申万菱信中证500指数优选增强A，目前规模为23.63亿元，最新净值2.1204，较上一交易日上涨0.32%，近一年上涨51.36%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083000010673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2562038902","title":"神州细胞(688520.SH)发布半年度业绩，归母净亏损3377万元，同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2562038902","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562038902?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:17","pubTimestamp":1756376231,"startTime":"0","endTime":"0","summary":"智通财经APP讯，神州细胞(688520.SH)披露2025年半年度报告，报告期公司实现营收9.72亿元，同比下降25.50%;归母净利润亏损3377万元，同比由盈转亏;扣非净利润亏损3611万元，同比由盈转亏;基本每股收益-0.10元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1337394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"神州细胞(688520.SH)发布半年度业绩，归母净亏损3377万元，同比由盈转亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2562038899","title":"图解神州细胞中报：第二季度单季净利润同比下降289.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562038899","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562038899?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:11","pubTimestamp":1756375870,"startTime":"0","endTime":"0","summary":"证券之星消息，神州细胞2025年中报显示，公司主营收入9.72亿元，同比下降25.5%；归母净利润-3377.11万元，同比下降126.87%；扣非净利润-3610.82万元，同比下降110.61%；其中2025年第二季度，公司单季度主营收入4.52亿元，同比下降34.66%；单季度归母净利润-9753.89万元，同比下降289.37%；单季度扣非净利润-5968.56万元，同比下降132.57%；负债率97.03%，投资收益36.6万元，财务费用4337.55万元，毛利率94.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800035165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2562082594","title":"神州细胞(688520)6月30日股东户数0.98万户，较上期减少12.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562082594","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562082594?lang=zh_cn&edition=full","pubTime":"2025-08-28 17:28","pubTimestamp":1756373305,"startTime":"0","endTime":"0","summary":"证券之星消息，近日神州细胞披露，截至2025年6月30日公司股东户数为9754.0户，较3月31日减少1424.0户，减幅为12.74%。在生物制品行业个股中，神州细胞股东户数低于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.42万户。从股价来看，2025年3月31日至2025年6月30日，神州细胞区间涨幅为46.91%，在此期间股东户数减少1424.0户，减幅为12.74%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800033216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2559302169","title":"8月14日神州细胞涨5.21%，申万菱信中证500指数优选增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2559302169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559302169?lang=zh_cn&edition=full","pubTime":"2025-08-14 16:16","pubTimestamp":1755159360,"startTime":"0","endTime":"0","summary":"证券之星消息，8月14日神州细胞涨5.21%，收盘报68.45元，换手率3.89%，成交量17.34万手，成交额11.98亿元。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共15家，其中持有数量最多的公募基金为申万菱信基金的申万菱信中证500指数优选增强A。申万菱信中证500指数优选增强A目前规模为23.63亿元，最新净值1.9682，较上一交易日上涨1.47%，近一年上涨35.84%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081400029873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000688.SH","510880","688520","510300","399006","159967","BK0239","000905.SH","159982","000001.SH","512880","399905","512510","000300.SH","515890","399001"],"gpt_icon":0},{"id":"2558157289","title":"药代和患者涉嫌骗保 神州细胞称公司未被调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2558157289","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558157289?lang=zh_cn&edition=full","pubTime":"2025-08-09 03:49","pubTimestamp":1754682540,"startTime":"0","endTime":"0","summary":"安佳因是神州细胞于2021年7月获批上市销售的血友病药品。据统计，上市销售4年，安佳因累计销售额已突破50亿元，并使长期亏损的神州细胞在2024年扭亏为盈。据了解，截至今年8月，全国多名神州细胞医药代表、患者卷入涉嫌骗保的案件中。神州细胞方面否认安佳因销售模式存在合规问题。前述裁判文书明确提及，神州细胞工程公司给予患者开药金额约4%的返点。药企以销售为目的给予患者返点涉嫌违反本条法规。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080904184194d86a02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080904184194d86a02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2557514606","title":"生物制品公司财务总监PK：百万年薪以上占比41% 神州细胞马洁年薪143万行业第三","url":"https://stock-news.laohu8.com/highlight/detail?id=2557514606","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557514606?lang=zh_cn&edition=full","pubTime":"2025-08-08 11:33","pubTimestamp":1754623980,"startTime":"0","endTime":"0","summary":" 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有24家上市生物制品公司，其聘任总体情况如下。其中，目前仍任职的最年轻的上市公司CFO年龄34岁，为智翔金泰-U的刘力文。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-08-08/doc-infkfuvz9163116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PK","688520","BK4218","BK0239","BK4181"],"gpt_icon":0},{"id":"2557111135","title":"生物制品公司财务总监PK：50岁以上CFO占比为38% 智翔金泰刘力文为业内最年轻CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2557111135","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557111135?lang=zh_cn&edition=full","pubTime":"2025-08-08 11:31","pubTimestamp":1754623903,"startTime":"0","endTime":"0","summary":"新浪财经《2024年度A股CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为81.48万元。从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到54%；50岁以上的CFO占比为38%；40岁及以下CFO占比为8%。其中，目前仍任职的最年轻的上市公司CFO年龄34岁，为智翔金泰-U的刘力文。从薪酬变动幅度看，2024年君实生物-U的许宝红薪酬降幅最大，同比降幅达24.66%；智翔金泰-U的刘力文薪酬增幅最大，同比涨幅达35.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808113149973af027&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808113149973af027&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688293","BK0239","688180","688443","688520","BK0216","688278"],"gpt_icon":0},{"id":"2557937530","title":"神州细胞今日主力净流出1.2亿 短期波动后看业绩兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2557937530","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557937530?lang=zh_cn&edition=full","pubTime":"2025-08-07 15:53","pubTimestamp":1754553214,"startTime":"0","endTime":"0","summary":"神州细胞今日主力资金净流出1.2亿元，上一交易日主力净流入1986.5万元。资金面与市场情绪共振引发短期波动近期神州细胞主力资金呈现多空博弈，政策红利与估值修正形成双向拉锯。截至8月5日，公司动态市盈率超300倍，显著高于行业均值，年内累计涨幅达93.62%，部分资金选择兑现收益，加剧了短期波动。随着业绩兑现能力成为估值锚点，商业化进程将主导长期走势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807163039a6d854e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807163039a6d854e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2556338991","title":"生物类似药集采启动，国内企业将迎接“价格战”","url":"https://stock-news.laohu8.com/highlight/detail?id=2556338991","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556338991?lang=zh_cn&edition=full","pubTime":"2025-08-04 23:24","pubTimestamp":1754321076,"startTime":"0","endTime":"0","summary":"今年1月，安徽省医保局年度工作安排中提到了生物药集采，明确表示“将牵头全国生物药品联盟集采”。2019年百奥泰和博锐生物的生物类似药相继上市后，国产阿达木单抗的年费降至3万元以下。在此之前，复宏汉霖曾公开表示，正在积极应对生物类似药集采可能带来的冲击，并通过生物类似药的“出海”来应对市场挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804232945a474ba81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804232945a474ba81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","LU0405327148.USD","LU1328615791.USD","LU1064130708.USD","LU1064131003.USD","LU2580892789.USD","02696","LU2495084118.USD","LU1655091616.SGD","06955","01276","LU1969619763.USD","688520","688177","BK0012","LU2148510915.USD","LU2580892862.HKD","LU0405327494.USD","BK0196","BK0183","LU2328871848.SGD","LU1997245094.SGD","LU1997245177.USD","BK0188","BK0239","BK0060","BK0028","688062","LU2488822045.USD","LU1997244956.HKD","01801"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766577495236,"stockEarnings":[{"period":"1week","weight":-0.0027},{"period":"1month","weight":-0.0535},{"period":"3month","weight":-0.2312},{"period":"6month","weight":-0.248},{"period":"1year","weight":0.1872},{"period":"ytd","weight":0.2062}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1367},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.1695}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京神州细胞生物技术集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13749人(较上一季度增加40.96%)","perCapita":"32390股","listingDate":"2020-06-22","address":"北京市大兴区北京经济技术开发区科创七街31号院5号楼307","registeredCapital":"44533万元","survey":" 北京神州细胞生物技术集团股份公司的主营业务是恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。公司的主要产品是SCT800（安佳因）、SCT400（安平希）、SCT630（安佳润）、SCT510（安贝珠）、SCT-I10A（安佑平）、SCT1000SCT650C、SCTC21C、SCTB35、SCTB14、SCTB41、SCTV02、SCTV04C、SCT520FF、SCTT11、SCTB39-1、SCTB39G、SCT640C。","listedPrice":25.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神州细胞,688520,神州细胞股票,神州细胞股票老虎,神州细胞股票老虎国际,神州细胞行情,神州细胞股票行情,神州细胞股价,神州细胞股市,神州细胞股票价格,神州细胞股票交易,神州细胞股票购买,神州细胞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}